Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Call 214-702-5225 or book online today.
Large-scale clinical trials have demonstrated that these modern metabolic treatments are highly effective, with semaglutide patients losing an average of 15% to 20% of their total body weight over 68 weeks
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns
In 2023, Eli Lilly synthesized injectable retatrutide, the first triple-action agonist targeting GLP-1, GIP, and glucagon receptors, which is currently undergoing Phase 3 clinical trials
US$ 28.29
US$ 28.60
US$ 20.10
US$ 25.21
